Get started
Author

Anna Wijatyk

Maribavir for Refractory or Resistant Cytomegalovirus Infections in Hematopoietic-cell or Solid-organ Transplant Recipients: A Randomized, Dose-ranging, Double-blind, Phase 2 Study
2018 · Genovefa A Papanicolaou, Fernanda P Silveira, et al. · Clinical Infectious Diseases · 226
PDF
Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation
2019 · Johan Maertens, Catherine Cordonnier, et al. · New England Journal of Medicine · 186
PDF
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
2015 · Michael Beck, Derralynn Hughes, et al. · Molecular Genetics and Metabolism Reports · 126
PDF
Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis
2017 · Yoichiro Natori, Ali Alghamdi, et al. · Clinical Infectious Diseases · 95
PDF
Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study
2014 · Raphael Schiffmann, Gregory M Pastores, et al. · Orphanet Journal of Rare Diseases · 37
PDF
Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease
2015 · Lubor Goláň, Ozlem Goker-Alpan, et al. · Drug Design Development and Therapy · 23
PDF
Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients
2016 · Johan Maertens, Catherine Cordonnier, et al. · Open Forum Infectious Diseases · 19
PDF
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa
2015 · Ozlem Goker-Alpan, Khan Nedd, et al. · JIMD Reports · 18
Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
2015 · Michael Beck, Derralynn Hughes, et al. · Molecular Genetics and Metabolism · 14
Maribavir for Treatment of Cytomegalovirus (CMV) Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant (SCT) or Solid Organ Transplant (SOT) Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
2016 · Genovefa Papanicolaou, Fernanda P. Silveira, et al. · Open Forum Infectious Diseases · 10
PDF
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
2024 · Nirav N. Shah, Richard T. Maziarz, et al. · Blood · 8
377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects
2020 · Claire Galand, Vignesh Venkatraman, et al. · Regular and Young Investigator Award Abstracts · 7
P1134: Bispecific Anti-cd20/19 Car-t – Zamtocabtagene Autoleucel for Relapsed/refractory Dlbcl – Interim Analysis Results of Daly-ii-usa Study
2023 · Nirav Shah, Richard Maziarz, et al. · HemaSphere · 6
398 AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy
2020 · Steven O’Day, Anthony El khoueiry, et al. · Regular and Young Investigator Award Abstracts · 4
Maribavir Versus Valganciclovir for Pre-Emptive Treatment of Cytomegalovirus Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant and Solid Organ Transplant Recipients
2017 · Johan A. Maertens, Catherine Cordonnier, et al. · Transplantation and Cellular Therapy · 4
256 Single-agent zalifrelimab (anti-CTLA-4) shows clinical benefit in rare tumors – case report from phase 2 study (NCT03104699)
2020 · Cesar Perez, Robert Wesolowski, et al. · Regular and Young Investigator Award Abstracts · 3
AGEN1181, a clinical stage Fc-engineered anti-CTLA-4 antibody with improved therapeutic potential for the treatment of patients with advanced malignancies.
2020 · Steven O'Day, Chethan Ramamurthy, et al. · Journal of Clinical Oncology · 3
Maribavir for Treatment of Cytomegalovirus Infections Resistant or Refractory to Ganciclovir or Foscarnet in Hematopoietic Stem Cell Transplant or Solid Organ Transplant Recipients: A Randomized, Dose-Ranging, Double-Blind, Phase 2 Study
2017 · Genovefa A. Papanicolaou, Fernanda P. Silveira, et al. · Transplantation and Cellular Therapy · 2
Intrathecal delivery of recombinant human arylsulfatase A in children with late-infantile metachromatic leukodystrophy
2016 · Christine Dali, Caroline Sevin, et al. · Molecular Genetics and Metabolism · 2
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma
2025 · Nancy M. Hardy, Jean A. Yared, et al. · Haematologica · 1
PDF
105 | Interim Results of Tandem Cd20‐cd19‐directed Non‐cryopreserved Car‐t Cells—zamtocabtagene Autoleucel in Relapsed/refractory Diffuse Large B Cell Lymphoma
2025 · N. N. Shah, R. T. Maziarz, et al. · Hematological Oncology · 1
PDF
Tandem CD20-CD19-Directed Non-Cryopreserved CAR T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
2025 · Nirav N. Shah, Richard T Maziarz, et al. · Transplantation and Cellular Therapy · 1
Agalsidase alfa in pediatric patients with Fabry disease: A 7-year open-label study
2013 · Raphael Schiffmann, Gregory Pastores, et al. · Molecular Genetics and Metabolism · 1
89 | Tandem Cd20‐19‐directed Non‐cryopreserved Car‐t Cells–zamtocabtagene Autoleucel (zamto‐cel)—in Patients With Relapsed/refractory Cns Lymphoma in Daly Ii Us Study
2025 · P. B. Johnston, D. B. Miklos, et al. · Hematological Oncology
PDF
Bispecific Anti‐cd20/19 Car‐t—zamtocabtagene Autoleucel for Relapsed/refractory Dlbcl—interim Analysis Results of Daly‐ii‐usa Study
2023 · M. Ulrickson, D. B. Miklos, et al. · Hematological Oncology
PDF
Works count: 30
Citation count: 797
H-index: 10
I10-index: 10
Year
Topic
Type